Relationship of serum prostate-specific antigen and alkaline phosphatase levels with bone metastases in patients with prostate cancer.
- Author:
Zhen-Lin WANG
1
;
Xiao-Fang WANG
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Aged, 80 and over; Alkaline Phosphatase; blood; Biomarkers, Tumor; blood; Bone Neoplasms; diagnostic imaging; secondary; Humans; Male; Middle Aged; Prostate-Specific Antigen; blood; Prostatic Neoplasms; blood; pathology; Radionuclide Imaging; Retrospective Studies; Sensitivity and Specificity
- From: National Journal of Andrology 2005;11(11):825-827
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the relation of serum prostate-specific antigen (PSA) and alkaline phosphatase (ALP) levels to bone metastases in patients with prostate cancer.
METHODSWe made a retrospective study of 96 cases of prostate cancer with (29 cases ) and without (67 cases ) bone metastases and evaluated their initial levels of serum PSA and ALP as well as the radionuclide bone scan findings.
RESULTSThe median concentrations of serum PSA and ALP were both in the bone scan-positive patients statistically higher than in those the negative ones (P < 0.01). The percentages of the bone scan-positive patients with PSA > 20 microg/L or ALP > 90 U/L were also higher than those with PSA < 20 microg/L or ALP < 90 U/L (P < 0.01).
CONCLUSIONProstate cancer patients with bone metastases have higher levels of PSA and ALP than those without. Radionuclide bone scan is necessary when the serum PSA level is > 20 microg/L and/or ALP level > 90 U/L.
